skip to Main Content
Get your free newsletter: Actionable insight each morning for self-directed investors. 

Though the wider FTSE 100 had an incredibly tough 2018, AstraZeneca shares were one of the best performers.

Opening at £51.20, a confident charge between early May and mid-November led the stock to a record peak of £64.33, only for the market’s end of the year worries to drag it to a 2018 closing price of £58.61.

After a brief spurt higher, January carried over that December decline, in part prompted by the departure of several senior executives in a C-suite shake-up. Having struck a 6-month low, news in February that a potential medicine to prevent respiratory syncytial virus in babies and infants had been granted special status in the US and Europe then put it on the path to recovery. AstraZeneca shares now sit at a current trading price of £57.17.

With a strong launch for its new medicines, especially in its cancer division, products sales for the third quarter rose 9% against the 3% forecast, breaking a streak that had seen 9 consecutive quarters of sales decline. For the 9 months to date product sales were up 4% to nearly $15.3 billion.

This caused investors to overlook a nasty 31% plunge in pre-tax profit to $1.26 billion, and a 6% slide in total revenue, as AstraZeneca continued to suffer from the loss of the patent for cholesterol drug Crestor.

Given that the company said that it now expects a ‘period of sustained growth for years to come’ there is going to be a lot of pressure on Thursday’s full year results to show that the sales surge wasn’t a one-off. AstraZeneca is expecting a ‘low single-digit’ percentage increase in product sales for the full year, alongside core earnings per share of between $3.30 and $3.50. Its guidance for the new financial year could also be key.

AstraZeneca shares have a consensus rating of ‘Buy’ alongside an average target price of £62.43.

This article is brought to you in association with Spreadex. All opinions expressed in this article are from the author and do not necessarily represent the opinions of The Armchair Trader. You can find out more about Spreadex products and services here, or find more articles from Connor Campbell here.

Please note this article does not constitute investment advice. Investors are encouraged to do their own research beforehand or consult a professional advisor.

Connor Campbell

Connor Campbell

Connor joined Spreadex in 2014 as part of a newly expanded financial analyst team after graduating from the University of Southampton with an MA in English. His focus is on providing Spreadex's customers with up-to-date and informative news, and is responsible for the market analysis found on the Spreadex website.

Connor produces three daily market updates, a daily stock earnings preview, a weekly financial market preview piece every Friday, a round-up of all the big financial stories making the weekend press every Monday morning and regular stock market features.

Stocks in Focus

Here are some of the smaller companies we are following most closely. They all represent significant growth stories in our view. Our in-depth reports go into more detail on why we like them.


Subscribe for more stories like this, 8am weekdays - for free!

Get your free daily newsletter: 

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
Back To Top